A New Approach to Psychiatric Drug Approval in Europe

PLoS Medicine

Volumn 10, Issue 10, 2013, Pages

  Barbui, Corrado ^a   Bighelli, Irene ^a  

^a UNIVERSITY OF VERONA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AGOMELATINE; CLOZAPINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR;

ARTICLE; DRUG APPROVAL; EUROPE; HUMAN; INSOMNIA; MAJOR DEPRESSION; MENTAL DISEASE; OUTCOME ASSESSMENT; PANIC; PRACTICE GUIDELINE; PSYCHIATRIC TREATMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCHIZOPHRENIA; SYSTEMATIC REVIEW (TOPIC); WORLD HEALTH ORGANIZATION;

DRUG APPROVAL; EUROPE; HUMANS;

EID: 84886602455     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.1001530     Document Type: Article

References (34)

1. Bighelli I, Barbui C, (2012) What is the European Medicines Agency? Epidemiol Psychiatr Sci 21: 245-247.
2. Duijnhoven RG, Straus SM, Raine JM, de BA, Hoes AW, De Bruin ML, (2013) Number of patients studied prior to approval of new medicines: a database analysis. PLoS Med 10: e1001407 doi:10.1371/journal.pmed.1001407.
3. Barbui C, Baschirotto C, Cipriani A, (2011) EMA must improve the quality of its clinical trial reports. BMJ 342: d2291.
4. Barbui C, Bighelli I, (2013) Regulatory science in Europe: the case of schizophrenia trials. Lancet pp. 381 In press.
5. European Medicines Agency (2010) Reflection paper on the need for active control in therapeutic areas where use of placebo is deemed ethical and one or more established medicines are available. European Medicines Agency EMA/759784/2010.
6. Bertele' V, Banzi R, Gluud C, Garattini S, (2012) EMA's reflection on placebo does not reflect patients' interests. Eur J Clin Pharmacol 68: 877-879.
7. Deshauer D, Moher D, Fergusson D, Moher E, Sampson M, Grimshaw J, (2008) Selective serotonin reuptake inhibitors for unipolar depression: a systematic review of classic long-term randomized controlled trials. CMAJ 178: 1293-1301.
8. Cipriani A, Purgato M, Barbui C, (2009) Why internal and external validity of experimental studies are relevant for clinical practice? Epidemiol Psichiatr Soc 18: 101-103.
9. Barbui C, Cipriani A, Lintas C, Bertele V, Garattini S, (2007) CNS drugs approved by the centralised European procedure: true innovation or dangerous stagnation? Psychopharmacology (Berl) 190: 265-268.
10. Food and Drug Administration (2010) Guidance for industry non-inferiority clinical trials. Rockville (Maryland): FDA.
11. Gotzsche PC, (2006) Lessons from and cautions about noninferiority and equivalence randomized trials. JAMA 295: 1172-1174.
12. Garattini S, Bertelé V, (2007) Non-inferiority trials are unethical because they disregard patients' interests. Lancet 370: 1875-1877.
13. Huitfeldt B, Hummel J, (2011) The draft FDA guideline on non-inferiority clinical trials: a critical review from European pharmaceutical industry statisticians. Pharm Stat 10: 414-419.
14. Mulla SM, Scott IA, Jackevicius CA, You JJ, Guyatt GH, (2012) How to use a noninferiority trial. JAMA 308: 2605-2611.
15. Hrobjartsson A, Thomsen AS, Emanuelsson F, Tendal B, Hilden J, Boutron I, et al. (2012) Observer bias in randomised clinical trials with binary outcomes: systematic review of trials with both blinded and non-blinded outcome assessors. BMJ 344: e1119.
16. Barbui C, Furukawa TA, Cipriani A, (2008) Effectiveness of paroxetine in the treatment of acute major depression in adults: a systematic re-examination of published and unpublished data from randomized trials. CMAJ 178: 296-305.
17. O'Connor AB, (2010) Building comparative efficacy and tolerability into the FDA approval process. JAMA 303: 979-980.
18. Psaty BM, Meslin EM, Breckenridge A, (2012) A lifecycle approach to the evaluation of FDA approval methods and regulatory actions: opportunities provided by a new IOM report. JAMA 307: 2491-2492.
19. Purgato M, Barbui C, (2012) What is the WHO essential medicines list? Epidemiol Psychiatr Sci 21: 343-345.
20. van Ommeren M, Barbui C, de JK, Dua T, Jones L, Perez-Sales P, et al. (2011) If you could only choose five psychotropic medicines: updating the interagency emergency health kit. PLoS Med 8: e1001030 doi:10.1371/journal.pmed.1001030.
21. Garattini S, Chalmers I, (2009) Patients and the public deserve big changes in evaluation of drugs. BMJ 338: b1025.
22. Garattini S, Bertele V, (2002) Efficacy, safety, and cost of new anticancer drugs. BMJ 325: 269-271.
23. Garattini S, Bertele' V, (2003) Efficacy, safety and cost of new cardiovascular drugs: a survey. Eur J Clin Pharmacol 59: 701-706.
24. Garattini S, Bertele' V, (2003) Efficacy, safety and cost of new drugs acting on the central nervous system. Eur J Clin Pharmacol 59: 79-84.
25. Barbui C, Cipriani A, (2012) Agomelatine and the brave old world of narrative-based medicine. Evid Based Ment Health 15: 2-3.
26. European Medicines Agency. Guideline on clinical investigation of medicinal products, including depot preparations in the treatment of schizophrenia. Available: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/10/WC500133437.pdf. Accessed 18 February 2013.
27. European Medicines Agency. Guideline on clinical investigation of medicinal products in the treatment of depression. Available: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/10/WC500116160.pdf. Accessed 18 February 2013.
28. European Medicines Agency. Note for guidance on clinical investigation of medicinal products for the treatment and prevention of bipolar disorder. Available: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003528.pdf. Accessed 18 February 2013.
29. European Medicines Agency. Guideline on the development of medicinal products for the treatment of post-traumatic stress disorder. Available: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003489.pdf. Accessed 18 February 2013.
30. European Medicines Agency. Guideline on medicinal products for the treatment of insomnia. Available: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/02/WC500102351.pdf. Accessed 18 February 2013.
31. European Medicines Agency. Guideline on the clinical investigation of medicinal products indicated for generalized anxiety disorder. Available: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003510.pdf. Accessed 18 February 2013.
32. European Medicines Agency. Guideline on clinical investigation of medicinal products indicated for the treatment of panic disorder. Available: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003511.pdf. Accessed 18 February 2013.
33. European Medicines Agency. Guideline on clinical investigation of medicinal products indicated for the treatment of social anxiety disorder. Available: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003490.pdf. Accessed 18 February 2013.
34. European Medicines Agency. Guideline on clinical investigation of medicinal products for the treatment of obsessive-compulsive disorder. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003512.pdf. Accessed 18 February 2013.